Severe asthma is linked to significant morbidity, health care resource utilization, and long-term sequelae including airway remodeling and a greater risk of developing chronic obstructive pulmonary disease. These consequences emphasize the importance of improved identification and management of patients with severe asthma. Treatment guidelines may be confusing and it may be challenging to keep abreast of new developments. Routine assessments of lung function, frequency and severity of exacerbati...

Better understanding of asthma pathophysiology has led to the development of targeted biologics that have improved outcomes for some patients with severe asthma, and the Global Initiative for Asthma (GINA) guidelines now include biologics in its guidelines for personalized therapy. This activity discusses the use of biologic therapies for severe asthma and provides guidance for managing several challenges, such as determining whether/when to initiate therapy, navigating challenges when prescribi...

Among asthma patients, those with severe asthma represent the greatest area of unmet clinical need; however, the emergence of new targeted biologics has improved outcomes for some of these patients. This activity looks at when biologic therapies for severe asthma are warranted, reviews approaches to tailoring the most appropriate targeted biologic agent to patients with severe asthma based on their phenotype and endotype, and discusses strategies for navigating administrative challenges when pre...